Phase 2 Hepatitis B Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to sign a consent form and fully understand what the trial involves, including its steps and possible side effects.
- Men and women between the ages of 35 and 65 (inclusive) who are able to complete the trial as required.
- People who do not plan to have children within the next year, and who agree to use the specific contraceptive methods outlined in the trial protocol from the screening stage until 6 months after the last dose.
- Men who weigh at least 50 kg and women who weigh at least 45 kg, with a body mass index (BMI) between 18 and 30 kg/m² (inclusive).
- People who have been on a stable antiviral treatment for hepatitis B (called NA therapy) for more than 6 months, and have stayed on the same treatment regimen for at least 3 months before the screening stage.
- People whose hepatitis B virus (HBV) levels in the blood have been sufficiently reduced, confirmed by at least two tests taken more than one week apart during the 28-day screening period, both showing HBV DNA below the minimum detectable level.
- People who test negative for a specific hepatitis B marker (HBeAg), have a hepatitis B surface antigen (HBsAg) level between 100 and 1500 IU/mL, and have normal liver enzyme (ALT) levels during screening (confirm with trial site).
- People who are able to communicate clearly with the clinical team and follow the trial requirements throughout.
Who may not be able to join:
- No exclusion criteria were listed in the provided information (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 13247651892
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
HBsAg decline from baseline at D168
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.